questionsmedicales.fr
Phénomènes chimiques
Phénomènes biochimiques
Conformation moléculaire
Conformation des protéines
Éléments structuraux des protéines
Motifs et domaines d'intéraction protéique
Motifs et domaines d'intéraction protéique : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Motifs et domaines d'intéraction protéique : Questions médicales les plus fréquentes",
"headline": "Motifs et domaines d'intéraction protéique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Motifs et domaines d'intéraction protéique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-22",
"dateModified": "2025-04-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Motifs et domaines d'intéraction protéique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Éléments structuraux des protéines",
"url": "https://questionsmedicales.fr/mesh/D000072416",
"about": {
"@type": "MedicalCondition",
"name": "Éléments structuraux des protéines",
"code": {
"@type": "MedicalCode",
"code": "D000072416",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Domaine B30.2-SPRY",
"alternateName": "B30.2-SPRY Domain",
"url": "https://questionsmedicales.fr/mesh/D000071197",
"about": {
"@type": "MedicalCondition",
"name": "Domaine B30.2-SPRY",
"code": {
"@type": "MedicalCode",
"code": "D000071197",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.290"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaine BTB-POZ",
"alternateName": "BTB-POZ Domain",
"url": "https://questionsmedicales.fr/mesh/D000071757",
"about": {
"@type": "MedicalCondition",
"name": "Domaine BTB-POZ",
"code": {
"@type": "MedicalCode",
"code": "D000071757",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.343"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Superfamille des domaines de mort",
"alternateName": "Death Domain Superfamily",
"url": "https://questionsmedicales.fr/mesh/D000071458",
"about": {
"@type": "MedicalCondition",
"name": "Superfamille des domaines de mort",
"code": {
"@type": "MedicalCode",
"code": "D000071458",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.395"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Domaine d'activation et de recrutement des caspases",
"alternateName": "Caspase Activation and Recruitment Domain",
"url": "https://questionsmedicales.fr/mesh/D000071476",
"about": {
"@type": "MedicalCondition",
"name": "Domaine d'activation et de recrutement des caspases",
"code": {
"@type": "MedicalCode",
"code": "D000071476",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.395.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaine de mort",
"alternateName": "Death Domain",
"url": "https://questionsmedicales.fr/mesh/D000071459",
"about": {
"@type": "MedicalCondition",
"name": "Domaine de mort",
"code": {
"@type": "MedicalCode",
"code": "D000071459",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.395.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaine effecteur de mort",
"alternateName": "Death Effector Domain",
"url": "https://questionsmedicales.fr/mesh/D000071461",
"about": {
"@type": "MedicalCondition",
"name": "Domaine effecteur de mort",
"code": {
"@type": "MedicalCode",
"code": "D000071461",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.395.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaine pyrine",
"alternateName": "Pyrin Domain",
"url": "https://questionsmedicales.fr/mesh/D000071196",
"about": {
"@type": "MedicalCondition",
"name": "Domaine pyrine",
"code": {
"@type": "MedicalCode",
"code": "D000071196",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.395.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Domaines FERM",
"alternateName": "FERM Domains",
"url": "https://questionsmedicales.fr/mesh/D000075926",
"about": {
"@type": "MedicalCondition",
"name": "Domaines FERM",
"code": {
"@type": "MedicalCode",
"code": "D000075926",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.422"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaines MYND",
"alternateName": "MYND Domains",
"url": "https://questionsmedicales.fr/mesh/D000074608",
"about": {
"@type": "MedicalCondition",
"name": "Domaines MYND",
"code": {
"@type": "MedicalCode",
"code": "D000074608",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.474"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaines PDZ",
"alternateName": "PDZ Domains",
"url": "https://questionsmedicales.fr/mesh/D054731",
"about": {
"@type": "MedicalCondition",
"name": "Domaines PDZ",
"code": {
"@type": "MedicalCode",
"code": "D054731",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaines à doigts de zinc de type RING",
"alternateName": "RING Finger Domains",
"url": "https://questionsmedicales.fr/mesh/D054829",
"about": {
"@type": "MedicalCondition",
"name": "Domaines à doigts de zinc de type RING",
"code": {
"@type": "MedicalCode",
"code": "D054829",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.625"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaine d'homologie SRC",
"alternateName": "src Homology Domains",
"url": "https://questionsmedicales.fr/mesh/D018909",
"about": {
"@type": "MedicalCondition",
"name": "Domaine d'homologie SRC",
"code": {
"@type": "MedicalCode",
"code": "D018909",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Motif stérile alpha",
"alternateName": "Sterile Alpha Motif",
"url": "https://questionsmedicales.fr/mesh/D000071682",
"about": {
"@type": "MedicalCondition",
"name": "Motif stérile alpha",
"code": {
"@type": "MedicalCode",
"code": "D000071682",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.813"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaine Tudor",
"alternateName": "Tudor Domain",
"url": "https://questionsmedicales.fr/mesh/D000071856",
"about": {
"@type": "MedicalCondition",
"name": "Domaine Tudor",
"code": {
"@type": "MedicalCode",
"code": "D000071856",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.844"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Domaines WW",
"alternateName": "WW Domains",
"url": "https://questionsmedicales.fr/mesh/D000074585",
"about": {
"@type": "MedicalCondition",
"name": "Domaines WW",
"code": {
"@type": "MedicalCode",
"code": "D000074585",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.820.709.275.750.500.937"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Motifs et domaines d'intéraction protéique",
"alternateName": "Protein Interaction Domains and Motifs",
"code": {
"@type": "MedicalCode",
"code": "D054730",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ylva Ivarsson",
"url": "https://questionsmedicales.fr/author/Ylva%20Ivarsson",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry-BMC, Uppsala University, Box 576, SE-751 23 Uppsala, Sweden. Electronic address: Yiva.ivarson@kemi.uu.se."
}
},
{
"@type": "Person",
"name": "Sobia Idrees",
"url": "https://questionsmedicales.fr/author/Sobia%20Idrees",
"affiliation": {
"@type": "Organization",
"name": "School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia."
}
},
{
"@type": "Person",
"name": "Keshav Raj Paudel",
"url": "https://questionsmedicales.fr/author/Keshav%20Raj%20Paudel",
"affiliation": {
"@type": "Organization",
"name": "Centre for Inflammation, Centenary Institute and Faculty of Science, School of Life Sciences, University of Technology Sydney, Australia."
}
},
{
"@type": "Person",
"name": "Per Jemth",
"url": "https://questionsmedicales.fr/author/Per%20Jemth",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biochemistry and Microbiology, Uppsala University, BMC Box 582, SE-75123 Uppsala, Sweden. Electronic address: Per.Jemth@imbim.uu.se."
}
},
{
"@type": "Person",
"name": "Norman E Davey",
"url": "https://questionsmedicales.fr/author/Norman%20E%20Davey",
"affiliation": {
"@type": "Organization",
"name": "Division of Cancer Biology, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Transplant program evaluations in the middle of the COVID-19 pandemic.",
"datePublished": "2022-07-04",
"url": "https://questionsmedicales.fr/article/35727854",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ajt.17123"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluating the sustainability of non-communicable diseases programs in Malaysia.",
"datePublished": "2022-08-01",
"url": "https://questionsmedicales.fr/article/35915493",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-022-13891-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Indigenous birth support worker (IBSW) program evaluation: a qualitative analysis of program workers and clients' perspectives.",
"datePublished": "2023-06-01",
"url": "https://questionsmedicales.fr/article/37259049",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12884-023-05695-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Recommendations After an Objective Structured Clinical Examination Program Evaluation.",
"datePublished": "2023-04-01",
"url": "https://questionsmedicales.fr/article/37001121",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3928/00220124-20230310-06"
}
},
{
"@type": "ScholarlyArticle",
"name": "An Early Evaluation of Remote Site Visits for ACGME Program Applications.",
"datePublished": "2023-04-17",
"url": "https://questionsmedicales.fr/article/37139198",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4300/JGME-D-22-00419.1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes chimiques",
"item": "https://questionsmedicales.fr/mesh/D055598"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes biochimiques",
"item": "https://questionsmedicales.fr/mesh/D001669"
},
{
"@type": "ListItem",
"position": 4,
"name": "Conformation moléculaire",
"item": "https://questionsmedicales.fr/mesh/D008968"
},
{
"@type": "ListItem",
"position": 5,
"name": "Conformation des protéines",
"item": "https://questionsmedicales.fr/mesh/D011487"
},
{
"@type": "ListItem",
"position": 6,
"name": "Éléments structuraux des protéines",
"item": "https://questionsmedicales.fr/mesh/D000072416"
},
{
"@type": "ListItem",
"position": 7,
"name": "Motifs et domaines d'intéraction protéique",
"item": "https://questionsmedicales.fr/mesh/D054730"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Motifs et domaines d'intéraction protéique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Motifs et domaines d'intéraction protéique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Motifs et domaines d'intéraction protéique",
"description": "Comment identifier un domaine d'interaction protéique ?\nQuels tests sont utilisés pour analyser les interactions protéiques ?\nLes motifs d'interaction peuvent-ils être prédits ?\nQuels marqueurs indiquent une interaction protéique ?\nComment les mutations affectent-elles les interactions protéiques ?",
"url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Program+Evaluation&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Motifs et domaines d'intéraction protéique",
"description": "Quels symptômes indiquent une dysfonction protéique ?\nLes interactions protéiques peuvent-elles causer des maladies ?\nComment les maladies génétiques affectent-elles les interactions ?\nQuels signes cliniques sont liés aux troubles d'interaction ?\nLes infections peuvent-elles perturber les interactions protéiques ?",
"url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Program+Evaluation&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Motifs et domaines d'intéraction protéique",
"description": "Comment prévenir les maladies liées aux interactions protéiques ?\nLes dépistages sont-ils utiles pour les troubles protéiques ?\nL'éducation sur les interactions protéiques est-elle importante ?\nLes vaccins influencent-ils les interactions protéiques ?\nComment le stress affecte-t-il les interactions protéiques ?",
"url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Program+Evaluation&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Motifs et domaines d'intéraction protéique",
"description": "Quels traitements ciblent les interactions protéiques ?\nComment la thérapie génique influence-t-elle les interactions ?\nLes inhibiteurs de protéines sont-ils efficaces ?\nComment les traitements ciblent-ils les motifs d'interaction ?\nLes thérapies combinées sont-elles bénéfiques ?",
"url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Program+Evaluation&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Motifs et domaines d'intéraction protéique",
"description": "Quelles complications peuvent survenir avec des interactions anormales ?\nLes complications sont-elles réversibles ?\nComment les interactions affectent-elles le vieillissement ?\nLes maladies auto-immunes sont-elles liées aux interactions ?\nLes troubles métaboliques sont-ils causés par des interactions ?",
"url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Program+Evaluation&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Motifs et domaines d'intéraction protéique",
"description": "Quels facteurs augmentent le risque de troubles protéiques ?\nLe vieillissement est-il un facteur de risque ?\nLes infections virales influencent-elles les interactions ?\nLe mode de vie peut-il affecter les interactions protéiques ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Program+Evaluation&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un domaine d'interaction protéique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des méthodes bioinformatiques et des expériences de biologie moléculaire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour analyser les interactions protéiques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le co-immunoprécipitation et les essais de double hybride."
}
},
{
"@type": "Question",
"name": "Les motifs d'interaction peuvent-ils être prédits ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des outils bioinformatiques permettent de prédire les motifs d'interaction dans les protéines."
}
},
{
"@type": "Question",
"name": "Quels marqueurs indiquent une interaction protéique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements de conformation ou des complexes protéiques stables peuvent indiquer une interaction."
}
},
{
"@type": "Question",
"name": "Comment les mutations affectent-elles les interactions protéiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations peuvent altérer la structure des motifs, perturbant ainsi les interactions normales."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une dysfonction protéique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme la fatigue, des troubles métaboliques ou des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les interactions protéiques peuvent-elles causer des maladies ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interactions anormales peuvent contribuer à des maladies comme le cancer ou Alzheimer."
}
},
{
"@type": "Question",
"name": "Comment les maladies génétiques affectent-elles les interactions ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des défauts dans les motifs d'interaction, perturbant les fonctions cellulaires."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont liés aux troubles d'interaction ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'inflammation, la douleur ou des anomalies neurologiques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles perturber les interactions protéiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains pathogènes modifient les interactions protéiques pour favoriser leur survie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées aux interactions protéiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Les dépistages sont-ils utiles pour les troubles protéiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages précoces peuvent aider à identifier des risques de maladies génétiques."
}
},
{
"@type": "Question",
"name": "L'éducation sur les interactions protéiques est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les interactions peut aider à prévenir des maladies et à promouvoir la santé."
}
},
{
"@type": "Question",
"name": "Les vaccins influencent-ils les interactions protéiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccins peuvent moduler les interactions immunitaires, renforçant la réponse du corps."
}
},
{
"@type": "Question",
"name": "Comment le stress affecte-t-il les interactions protéiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut altérer les interactions protéiques, affectant la santé globale et le bien-être."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les interactions protéiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de protéines ou des anticorps monoclonaux sont utilisés."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique influence-t-elle les interactions ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut corriger des mutations, rétablissant ainsi des interactions protéiques normales."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs de protéines sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent bloquer des interactions spécifiques, offrant des options thérapeutiques."
}
},
{
"@type": "Question",
"name": "Comment les traitements ciblent-ils les motifs d'interaction ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils visent à modifier ou à bloquer des motifs spécifiques pour restaurer la fonction cellulaire."
}
},
{
"@type": "Question",
"name": "Les thérapies combinées sont-elles bénéfiques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent cibler plusieurs interactions protéiques, améliorant l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des interactions anormales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des cancers, des maladies neurodégénératives ou des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment les interactions affectent-elles le vieillissement ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interactions protéiques altérées peuvent accélérer le vieillissement cellulaire et tissulaire."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles liées aux interactions ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interactions anormales peuvent déclencher des réponses auto-immunes dans l'organisme."
}
},
{
"@type": "Question",
"name": "Les troubles métaboliques sont-ils causés par des interactions ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interactions protéiques défectueuses peuvent entraîner des déséquilibres métaboliques."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de troubles protéiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme la génétique, l'environnement et le mode de vie influencent le risque."
}
},
{
"@type": "Question",
"name": "Le vieillissement est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la stabilité et la fonction des interactions protéiques."
}
},
{
"@type": "Question",
"name": "Les infections virales influencent-elles les interactions ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber les interactions protéiques, augmentant les risques."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il affecter les interactions protéiques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée et le manque d'exercice peuvent altérer les interactions."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des toxines ou des polluants peuvent affecter les interactions protéiques et la santé."
}
}
]
}
]
}
Potential regional variations in effects of COVID-19 on federally mandated, program-specific evaluations by the Scientific Registry of Transplant Recipients (SRTR) have been controversial. SRTR Januar...
The substantial rise in non-communicable diseases (NCDs) over the last two decades poses a major concern to the healthcare services in Malaysia. This study aimed to evaluate the sustainability of the ...
This study applied the mixed-method approach using the Program Sustainability Assessment Tool (PSAT) to assess the eight domains for program sustainability combined with 5 open-ended questions. The su...
A total of 80 key leaders responded to the survey. Overall seven domains scored an average of ≥ 4 with an overall mean sustainability score of 4.2. The highest domain mean scores were 4.5 (communicati...
The sustainability factors affecting the NCDs program in Malaysia are qualitatively similar to other countries. For greater sustainability capacity, we should work towards strong leadership, strengthe...
The Indigenous Birth Support Worker (IBSW) Program provides Indigenous women with respectful, culturally safe, and trauma-informed care and supports women and families during labor and delivery. Locat...
The study objective was to explore the perspectives of the IBSWs and program clients one year post-implementation. The research plan was developed in collaboration with the IBSW program director and m...
Thematic analysis revealed that clients greatly appreciated and respected the IBSWs' cultural support and their compassionate, nonjudgmental, and safe care. IBSWs emphasized the importance of cultural...
The Indigenous Birth Support Worker (IBSW) Program provides safe and client-centred care to Indigenous women during pregnancy, labour, and postpartum, consistent with the six principles proposed by BC...
The use of objective structured clinical examinations (OSCEs) is a well-established method of clinical assessment in the medical profession, and these are currently being integrated into advanced prac...
A program assessment was conducted at a current family nurse practitioner track within a southwestern U.S. university using the OSCE evaluative strategy. The logic model from the Centers for Disease C...
Strengths and challenges were found in the areas of student preparation, scoring/grading with variations of inter-rater reliability, and debriefing....
Establishing a specific OSCE center with a dedicated director could support adequate attainment of formative and summative competencies for nurse practitioners and provide faculty education and standa...
Prior to the COVID-19 pandemic, accreditation site visit interviews occurred in-person. In response to the pandemic, the Accreditation Council for Graduate Medical Education (ACGME) developed a remote...
To perform an early assessment of the remote accreditation site visits for programs applying for initial ACGME accreditation....
A cohort of residency and fellowship programs that had remote site visits was evaluated from June to August 2020. Surveys were sent to program personnel, ACGME accreditation field representatives, and...
Surveys were sent to all program personnel from the 58 residency and fellowship programs that had remote site visits for new program applications, as well as the accreditation field representatives wh...
Most program personnel and accreditation field representatives were confident that remote site visits conducted for program applications provided fair and thorough assessments of the program....
This study aims to analyze the feasibility of building an evaluative model for the management of the Tuberculosis Prevention and Control Program in the State of Roraima, located on the border between ...
In this paper, a backward mapping approach to realist evaluation is used to evaluate the efficacy of an international inclusive education short course program in transforming inclusive perspectives an...
There is an urgency to retain nurses globally. Evidence has shown that nurse residency programs promote retention of new graduate nurses. However, there is a dearth of studies examining the impact of ...
To evaluate the impact of a transition-to-practice program on new graduate nurses' practice confidence and job satisfaction over 24 months....
A retrospective longitudinal study....
A 1200-bed public tertiary academic hospital....
New graduate nurses from local universities who joined the hospital and were enrolled in the Graduate Nurse Residency Program (n = 104)....
The program was conducted for 24 months and consisted of modules on bedside knowledge and skills, and a mentorship program with senior nurse leaders. Practice confidence and job satisfaction were meas...
Practice confidence increased and job satisfaction decreased over the 24 months. Practice confidence total score at 6 months and an extended probation period were factors associated with attrition dur...
This is the first longitudinal study to demonstrate the impact of a transition-to-practice program in a multiethnic Asian setting. The Graduate Nurse Residency Program enhanced the practice confidence...
The use of the meta-evaluation, especially in health promotion programs, is still scarce....
To verify if the evaluation studies conducted about the Academia da Cidade Programme and the Academia da Saúde Programme comply with the principles and standards of the meta-evaluation....
This meta-evaluation study was conducted using articles from scientific databases. The parameters of utility, propriety, and accuracy, as defined by the Joint Committee on Standards for Educational Ev...
Of the 18 selected articles, the principle of utility was fully met in 50%, given that 27.8% were classified as very good, 5.6% as good, and 16.7% as fair. The principle of propriety mostly received t...
The physical activity community programs evaluations were carried out in accordance to the principles and standards of meta-evaluation tenets. Most studies were classified as excellent regarding the p...
Evaluation of public programs has undergone many changes over the past four decades since Peter Rossi coined his "Iron Law" of program evaluation: "The expected value of any net impact assessment of a...